Skip to main content
. 2022 Aug 1;14(8):529. doi: 10.3390/toxins14080529

Figure 3.

Figure 3

Forest plot of the results of the meta-analysis for the comparison of the onabotulinumtoxinA used in combination with anti-CGRP mAbs and alone about the efficacy primary outcome change in mean of monthly headache days (MHDs) after 3 months.